ZelleRx

ZelleRx Corporation was a biotechnology company founded in 2002 by Dr. Hans Klingemann, focused on developing natural killer (NK) cell therapies for cancer. The company was built around the proprietary NK-92 cell line, which offers a standardized, "off-the-shelf" approach to immunotherapy by utilizing a unique population of cytotoxic cells. Over the years, ZelleRx underwent several corporate transformations, rebranding as Conkwest in 2010 and NantKwest in 2015 before ultimately merging with ImmunityBio in 2021. Today, its foundational NK cell technology is a core component of ImmunityBio's clinical pipeline, which targets various solid and liquid tumors. The company's legacy represents a significant milestone in the development of allogeneic cellular immunotherapies.